MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
0.1731
-0.5457
-75.92%
Opening 10:50 08/28 EDT
OPEN
0.2122
PREV CLOSE
0.7188
HIGH
0.2299
LOW
0.1699
VOLUME
34.76M
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
0.1699
MARKET CAP
5.42M
P/E (TTM)
-0.0458
1D
5D
1M
3M
1Y
5Y
1D
Dow Gains 100 Points; Chicago PMI Falls In August
Benzinga · 43m ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 2h ago
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Benzinga · 4h ago
BioXcel Therapeutics Initiates Chapter 11 and Sale Process
TipRanks · 4h ago
BioXcel Files for Bankruptcy With Deal to Sell Assets to Teva
Dow Jones · 4h ago
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics
TipRanks · 4h ago
BioXcel files for Chapter 11, will sell assets to Teva
Seeking Alpha · 4h ago
BioXcel Therapeutics Agrees To Teva Asset Sale
NASDAQ · 4h ago
More
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.